The Prostate Oncology Program is uniquely positioned to make historic advancements in the prevention, research and treatment of prostate cancer.
A multi-disciplinary team of medical oncologists, radiation oncologists, urologic oncologists, pathologists, radiologists, nurses, social workers, nurse navigators, and researchers, are united in one goal - eradicating prostate cancer. To reach that goal, we have created a prostate cancer research and treatment program of extraordinary quality. It is a place where research discoveries are applied to prevention and treatment, and where compassionate care is given to patients, their families and friends. Cutting-edge clinical trials are a central component of the Prostate Oncology Program.
Our physicians see patients here in New Brunswick as well as at Monmouth Medical Center, an RWJBarnabas Health facility, and at University Hospital Newark.
Rutgers Cancer Institute of New Jersey is a leader in laparoscopic renal procedures and has extensive experience with robotic prostatectomy. The major advantages of robotic prostatectomy include shorter hospital stays, lower blood loss, and faster recovery. Given that robotic surgery is a relatively new technology, surgeon experience is critical for good outcome. Under the leadership of the Urologic Oncology Program, Rutgers Cancer Institute of New Jersey has developed a center of excellence for robotic surgery and its urologic oncologists have performed more than 2,000 robotic prostatectomies.
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, earned several High Performing ratings in the 2023-2024 U.S. News & World Report Best Hospitals survey, including for prostate cancer surgery.
To request an appointment, call 844-CANCERNJ. | Find Prostate Oncology Clinical Trials.
- Medical Oncologist
- Associate Professor, Rutgers Robert Wood Johnson Medical School
- Medical Oncologist
- Associate Professor of Medicine, Division of Medical Oncology, and Section of Solid Tumor, Rutgers Robert Wood Johnson Medical School
- Medical Oncologist
- Assistant Professor of Medicine
- Chief of Urologic Oncology, Rutgers Cancer Institute of New Jersey
- Program Director, Urology Residency Program, Rutgers Robert Wood Johnson Medical School
- Associate Professor, Rutgers Robert Wood Johnson Medical School
- Urologic Oncologist
- Director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute of New Jersey
- Assistant Professor of Surgery, Rutgers Robert Wood Johnson Medical School
- Urologic Oncologist
- Associate Professor, Department of Surgery and Division of Urology at Rutgers Robert Wood Johnson Medical School
- Medical Director, Clinical Network for Radiation Oncology
- Radiation Oncologist
- Medical Director, Laurie Proton Therapy Center
- Radiation Oncologist
- Professor of Radiation Oncology, Rutgers Robert Wood Johnson Medical School
- Advanced Practice Nurse
- Advanced Practice Nurse
- Advanced Practice Provider
- Advanced Practice Provider
- Advanced Practice Provider
- Physician Assistant
- Nurse Clinician
Rutgers Cancer Institute' s Dr. Saum Ghodoussipour discusses the new therapy mitomycin gel, which is the first non-surgical treatment for urothelial cancer.
Project HERO: Health Empowerment & Recovery Outcomes
The purpose of the research is to: determine whether usual care, or a body training program, or a body-mind training program may help improve health and well-being in 166 senior men with a diagnosis of cancer.
